MOESM1 of A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?

Additional file 1. Blood flow and pulsation measurements

Additional file 2: of Differential methylation at MHC in CD4+ T cells is associated with multiple sclerosis independently of HLA-DRB1

Gene set analysis of top CpG hits. Output of results from ORA analysis using Webgestalt. (XLSX 46.8 kb

Additional file 3: of Differential methylation at MHC in CD4+ T cells is associated with multiple sclerosis independently of HLA-DRB1

Individual methylation (Beta value) distribution for top hit. Plots showing the distribution of beta values for case and control group for the top CpG in the RNF39 gene illustrating the DMP is not due to SNP genotype. An example of genotype influenced methylation spread is also shown for comparison. (PDF 113 kb

Additional file 2: of Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

Table S2. Erythrocyte purity determined by flow cytometry (n = 10). Data is shown as mean percent positive events out of 20,000 events. (XLSX 12 kb

Additional file 3: of Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

Figure S1. Total erythrocyte RNA extracted from 10 ml whole blood by disease-modifying therapy. Mean total erythrocyte RNA yields from 10 ml whole blood for 2 patients off treatment, 2 on dimethyl fumarate, 13 on fingolimod, 12 on natalizumab and 27 healthy controls. Error bars represent standard deviation (SD). ** p < 0.01; *** p < 0.001. (PNG 41 kb

Additional file 1: of Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

Table S1. Next-generation sequencing results of erythrocyte microRNAs for 9 healthy controls and 9 relapsing-remitting Multiple Sclerosis patients. (XLSX 27 kb

Additional file 4 of Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

Figure S2. Tukey boxplot of relative expression (2-deltaCt) of differentially expressed erythrocyte microRNAs in the sequencing cohort by disease-modifying therapy. Relative expression (2-deltaCt) (y-axis on a logarithmic scale) of differentially expressed erythrocyte miRNAs (x-axis) by disease-modifying therapy (fingolimod: n = 3; natalizumab: n = 2; dimethyl fumarate: n = 2; off treatment: n = 2) and including healthy controls (n = 5). The dots represent outliers defined as deviating ≥1.5 fold from the upper/lower quartile. (PNG 29 kb

Additional file 1: Figure S1. of Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells

Volcano plot of differentially expressed miRNAs identified with NGS. The FDR-corrected significance threshold is demarked with a green line at p < 1.2 × 10−4. Three miRNAs were identified at the threshold. Mean read counts were low in all three miRNAs: miR-451a (SPMS mean = 76.3, HC mean = 18.9), miR-1246 (SPMS mean = 94.9, HC mean = 51.9), and miR-144-5p (SPMS mean = 15.1, HC mean = 5.5). Differential expression could not be replicated with RT-qPCR. (PNG 57 kb

Supplemental material for DNA methylation changes in CD4⁺ T cells isolated from multiple sclerosis patients on dimethyl fumarate

<p>Supplemental material for DNA methylation changes in CD4⁺ T cells isolated from multiple sclerosis patients on dimethyl fumarate by Vicki E Maltby, Rodney A Lea, Karen A Ribbons, Katherine A Sanders, Daniel Kennedy, Myintzu Min, Rodney J Scott and Jeannette Lechner-Scott in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p

Predictors of first treatment discontinuation.

<p>Abbreviations: n: number, HR: Hazard Ratio, CI: Confidence Interval, IFN: Interferon, IM: intramuscular, SC: Subcutaneous, GA: Glatiramer Acetate, EDSS: Expanded Disability Status Scale.</p><p>Treatment initiations n = 760 excluding Natalizumab (n = 11).</p>α<p>Cox Proportional Hazards Regression.</p><p>Multivariable Cox Proportional Hazards model was adjusted for sex, disease duration, age at treatment start, treatment and EDSS.</p><p># Proportional hazards test: p = 0.3747.</p>*<p>No EDSS score available at the time of treatment start.</p